Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neurology
•
Neuro-immunology
When do you consider disease modifying therapy in radiographically isolated syndrome?
Does reclassification of RIS as MS in upcoming McDonald Criteria change this decision for you?
Related Questions
What is the diagnostic approach and management for suspected Hashimoto Encephalitis?
Do you have any clinical experience regarding the administration of B cell depleting therapies in MS patients with splenectomy?
How does one interpret an SPEP showing potentially obscured but non-quantifiable M-spike however an IFE showing monoclonal protein?
Do you consider steroid-sparing agents for treatment of patients with steroid responsive relapsed Hashimoto Encephalopathy?
How does your decision to use high-efficacy disease-modifying treatments (HET) differ, if at all, when treating late-onset relapsing-remitting multiple sclerosis?
How do you counsel women on anti-CD20 therapy for MS who are planning for pregnancy?
How can we minimize the risk of overinterpreting reactive findings from repeat lumbar punctures?
In a patient with strong serologic evidence of SLE presenting with isolated bilateral lower limb sensorimotor neuropathy, normal neuroimaging, and CSF, would you initiate cyclophosphamide with pulse-dose steroids upfront, or reserve escalation (e.g., plasma exchange or immunosuppressants) for cases refractory to steroids?
What are your vaccine recommendations while patients are on biologics?
Should IVIG dosing in patients with autoimmune disease (i.e., dermatomyositis) who become pregnant continue to be based on actual weight at the time of each infusion, or should it be limited to pre-pregnancy weight?